Shire to present Vyvanse, Intuniv studies at psychiatrist meetings Drug Store News The company said it would present data on Vyvanse (lisdexamfetamine dimesylate) capsules and Intuniv (guanfacine) extended-release tablets at two ... and more » |
Court rebuffs Actavis on Vyvanse FiercePharma A US district court judge in DC has upheld an FDA decision to grant five years of market exclusivity to Shire's ADHD drug Vyvanse (lisdexamfetamine), ... Shire: District Court Upholds FDAs Grant of 5-Year Exclusivity Wall Street Journal Actavis Loses to FDA in ADHD Drug Ruling Courthouse News Service Shire given market exclusivity for ADHD drug Drug Store News (blog) FOXBusiness - Pharma Times all 36 news articles » |
Shire settles dispute with Teva Financial Times A surge in prescriptions for ADHD in both children and adults in recent years has boosted use of the medicines, further stimulated by price cuts since the ... Shire, Teva settle litigation over ADHD drugDrug Store News (blog) Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized ...PR Newswire (press release) all 37 news articles » |
US FDA reaffirms five-year NCE exclusivity to Shire's Vyvanse pharmabiz.com The five-year exclusivity period for Vyvanse expires on February 23, 2012. Vyvanse is covered by United States patents which remain in effect until June 29, ... Shire receives market exclusivity for ADHD drug Drug Store News (blog) all 3 news articles » |
Shire celebrates as FDA backs Vyvanse exclusivity Pharma Times Shire has received a boost with the news that regulators in the USA have confirmed that the attention-deficit hyperactivity disorder drug Vyvanse is ... US FDA reaffirms five-year NCE exclusivity to Shire's Vyvanse pharmabiz.com Shire receives market exclusivity for ADHD drug Drug Store News (blog) all 3 news articles » |